Baotai Liang
Clinical trials sponsored by Baotai Liang, explained in plain language.
-
New combo therapy aims to shrink prostate cancer before surgery
Disease control Recruiting nowThis study is testing whether adding two new drugs (fasudil hydrochloride and a PD1 inhibitor) to standard hormone therapy before prostate cancer surgery works better than standard therapy alone. The goal is to see if this combination shrinks the cancer more effectively, potentia…
Phase: PHASE2, PHASE3 • Sponsor: baotai Liang • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo tested to shrink prostate cancer before surgery
Disease control Recruiting nowThis study is testing whether adding a drug called homoharringtonine to standard hormone-blocking therapy can better shrink prostate cancer before surgery. It aims to see if this combination leads to less cancer remaining after surgery and improves long-term results. The study is…
Phase: PHASE2 • Sponsor: baotai Liang • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat prostate cancer?
Disease control Recruiting nowThis study is testing whether adding a drug called fasudil hydrochloride to immunotherapy helps control advanced prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. It will involve about 30 men who have already tried other treatmen…
Phase: PHASE2 • Sponsor: baotai Liang • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug combo aims to wipe out prostate cancer before surgery
Disease control Recruiting nowThis study is testing if adding a drug called homoharringtonine to standard hormone therapy before prostate cancer surgery is more effective. The goal is to see if this combination can better shrink or eliminate the cancer, potentially leading to better long-term outcomes. The tr…
Phase: PHASE2 • Sponsor: baotai Liang • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC